Protalex Inc (PRTX) 2.2101 $PRTX Protalex Receives

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Protalex Inc (PRTX) 2.2101 $PRTX

Protalex Receives Positive Interim Review from Independent Safety Monitoring Committee in Its European Phase 1b Study of PRTX-100 to Treat Immune Thrombocytopenia
BusinessWire - Mon May 02, 7:00AM CDT
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, today announced that following a planned interim data review by its independent Safety Monitoring Committee (SMC), the Company is continuing enrollment and increasing the dose for subjects in its European Phase 1b study of PRTX-100 in adults with persistent/chronic Immune Thrombocytopenia (ITP) (PRTX-100-203 Study). The dose of PRTX-100 for subjects in the next treatment group (6.0 micrograms/kg) will be twice that of the initial starting dosage (3.0 micrograms/kg).

Protalex Announces Preliminary Findings from Phase I/II Continuation Trial of PRTX-100 in Active Rheumatoid Arthritis Patients
BusinessWire - Mon Apr 25, 7:00AM CDT
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, today announced preliminary findings following completion of its Phase I/II open-label, single group study with former participants from its U.S.-based PRTX-100-104 Study. In this continuation study ("PRTX-100-105 Study" , rheumatoid arthritis (RA) patients received a fixed dose of PRTX-100 over a 6-month period in combination with either methotrexate or leflunomide.

Four Biotechs To Consider On Intermediate Bottom, Trend Change Signal
ACCESSWIRE - Mon Mar 14, 9:10AM CDT
NEW YORK, NY / ACCESSWIRE / March 14, 2016 / 2015 was a wild year in biotech, with six months of sector-wide gains during January to July reversed throughout the latter half of the year on a combination of political reform expectations and US rate-hike-induced risk-off sentiment. We're nearly a full quarter into 2016, and it looks like we may have finally seen an intermediate bottom in stocks with yesterday's big up move holding today, March 2.
SQNM: 2.36 (+0.02), CDTX: 11.72 (-0.19), ATHX: 2.01 (unch)

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutic Development Pipeline Review, H2 2015
M2 - Wed Jan 27, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/8qf3c9/idiopathic) has announced the addition of the "Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview - Therapeutics Development - Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview - Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Comparative Analysis - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics under Development by Companies - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics under Investigation by Universities/Institutes - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Products under Development by Companies - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Products under Investigation by Universities/Institutes - Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development - 3SBio Inc. - Amgen Inc. - Baxalta Incorporated - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Eisai Co., Ltd. - Hansa Medical AB - Immunomedics, Inc. - Intas Pharmaceuticals Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - Merck & Co., Inc. - Momenta Pharmaceuticals, Inc. - Novartis AG - Pfizer Inc. - PhytoHealth Corporation - Protalex, Inc. - Rigel Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/8qf3c9/idiopathic
IMMU: 2.98 (+0.09), PFE: 34.84 (-0.14), AMGN: 174.35 (+0.73), BMY: 59.26 (-0.03), RIGL: 2.81 (-0.09), MNTA: 12.33 (+0.39), MRK: 63.55 (+0.19), BXLT: 46.02 (-0.18), NVS: 81.32 (-0.02)

Protalex Announces First Patient Dosed in European Phase Ib Study of PRTX-100 for Immune Thrombocytopenia
BusinessWire - Thu Jan 07, 7:30AM CST
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, today announced dosing of the first patient in its European Phase Ib study of PRTX-100 in adults with persistent/chronic Immune Thrombocytopenia (ITP) (the PRTX-100-203 Study). PRTX-100, Protalex's lead drug candidate, is a highly purified form of Staphylococcal protein A (SpA), which was granted Orphan Drug Designation in Europe and the U.S. for the treatment of ITP. A similar Phase I/II clinical study of PRTX-100 is underway in the U.S. (the PRTX-100-202 Study). PRTX-100 is also the subject of ongoing clinical development in Rheumatoid Arthritis (RA).

Protalex Could Be an Early Stage Buyout Target come February
ACCESSWIRE - Mon Nov 23, 10:00AM CST
NEW YORK, NY / ACCESSWIRE / November 23, 2015 / In the rheumatoid arthritis (RA) treatment space, Humira is king. The drug generated $11 billion revenues for AbbVie Inc. (ABBV) during 2014, accounting for more than 60% of the company's total revenues and forecast to generate between $13 billion and $18 billion by 2020. The drug is a TNF inhibitor - it binds to tumor necrosis factor-alpha (TNFα), stopping the TNFα from binding to TNFα receptors - the process that initiates the inflammatory immune response and causes RA.

Protalex Announces First Patient Dosed in U.S. Phase 1/2 Study of PRTX-100 for Immune Thrombocytopenia
BusinessWire - Mon Nov 23, 7:30AM CST
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, today announced that it has dosed the first patient in its U.S. Phase 1/2 study of PRTX-100 in adults with persistent/chronic Immune Thrombocytopenia (ITP) (PRTX-100-202 Study). PRTX-100, Protalex's lead drug candidate, is a highly purified form of Staphylococcal protein A (SpA), which was recently granted Orphan Drug Designation in the U.S. and in Europe for the treatment of ITP. PRTX-100 is also the subject of ongoing clinical development in Rheumatoid Arthritis (RA).

Protalex Announces Presentation of Preclinical Data with PRTX-100 Supporting Treatment of Immune Thrombocytopenia at the American Society of Hematology 57th Annual Meeting and Exposition
BusinessWire - Wed Nov 11, 7:30AM CST
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, today announced that an abstract highlighting preclinical results from a study of Staphylococcal protein A (PRTX-100) for the treatment of Immune Thrombocytopenia (ITP) will be presented at the upcoming American Society of Hematology (ASH) 57th Annual Meeting and Exposition being held in Orlando, Florida from December 5-8, 2015. The abstract is available on the ASH website at http://www.hematology.org and on the Company's website at www.protalex.com.

Protalex passes French National Agency for Medicines and Health Products' approval to begin Phase Ib study of PRTX-100 in adult patients with persistent/chronic immune thrombocytopenia
M2 - Tue Oct 06, 5:41AM CDT
Biopharmaceutical company Protalex (OtherOTC RTX) reported on Monday the receipt of the French National Agency for Medicines and Health Products' (ANSM) approval to begin a Phase Ib study of PRTX-100 in adult patients with persistent/chronic immune thrombocytopenia (ITP), an autoimmune-mediated condition characterised by bruising and increased bleeding as a result of immune-mediated accelerated destruction of platelets and impaired production of platelets.

Protalex Announces Regulatory Approval to Initiate Phase Ib Trial of PRTX-100 to Treat Immune Thrombocytopenia in France
BusinessWire - Mon Oct 05, 7:00AM CDT
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, announced today that the French National Agency for Medicines and Health Products (ANSM) has approved the company's clinical trial application to begin a Phase Ib study of PRTX-100 in adult patients with persistent/chronic immune thrombocytopenia (ITP). This approval authorizes Protalex to initiate the study (PRTX-100-203 Study) at several sites in France. The company expects to commence enrollment before year end.

Protalex to launch US Phase I/II trial of PRTX-100 in immune thrombocytopenia patients
M2 - Fri Sep 04, 3:05AM CDT
Biopharmaceutical company Protalex (Other OTC RTX) said on Thursday that it will begin enrollment under its Phase I/II study of PRTX-100 in adult patients with persistent/chronic immune thrombocytopenia (ITP) at several sites in the United States (the PRTX-100-202 Study) in the coming weeks.

Protalex to Initiate Enrollment of U.S. Phase I/II Trial of PRTX-100 to Treat Immune Thrombocytopenia
BusinessWire - Thu Sep 03, 7:00AM CDT
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, announced today that it will initiate enrollment for a Phase I/II study of PRTX-100 in adult patients with persistent/chronic immune thrombocytopenia (ITP) at several sites in the United States (the PRTX-100-202 Study) in the coming weeks. Protalex previously announced U.S. FDA acceptance of an Investigational New Drug application (IND) for this study. PRTX-100, Protalex's lead drug, is a new generation immunomodulatory therapy that is under investigation for autoimmune diseases such as rheumatoid arthritis (RA) and ITP. PRTX-100 is a highly purified form of Staphylococcal protein A (SpA), a bacterial protein known to modify aspects of the human immune system.

Thrombocytopenia Pipeline Review, H1 2015 - 35 Companies & 41 Drug Profiles
M2 - Fri Jul 31, 8:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jqnh8b/thrombocytopenia) has announced the addition of the "Thrombocytopenia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombocytopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocytopenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ablynx NV - Anthera Pharmaceuticals Inc. - Archemix Corp. - Arcturus Therapeutics, Inc - aTyr Pharma, Inc. - Bayer AG - BioLineRx, Ltd. - Boehringer Ingelheim GmbH - Bolder Biotechnology, Inc. - Bristol-Myers Squibb Company - Cellerant Therapeutics, Inc. - Eisai Co., Ltd. - GlaxoSmithKline Plc - Glenmark Pharmaceuticals Ltd. - HanAll Biopharma Co., Ltd. - Immunomedics, Inc. - InvivoGen Therapeutics - Jiangsu Hengrui Medicine Co., Ltd. - Kaketsuken K.K. - Merck & Co., Inc. - Momenta Pharmaceuticals, Inc. - Myelo Therapeutics GmbH - Neumedicines Inc. - Novartis AG - Octapharma AG - Omeros Corporation - Pfizer Inc. - PhytoHealth Corporation - Portola Pharmaceuticals, Inc. - Prophylix Pharma AS - Protalex, Inc. - Rigel Pharmaceuticals, Inc. - Shionogi & Co., Ltd. - STATegics, Inc. - ViroMed Co., Ltd. Drug Profiles - Antibody for Autoimmune Disorders and Inflammation - ARC-15105 - avatrombopag - BAX-930 - BBT-030 - BBT-045 - BI-655064 - BL-8040 - blisibimod - BMS-986004 - caplacizumab - CLT-009 - eltrombopag olamine - fostamatinib disodium - GBR-600 - Gene Therapy for Chemotherapy-Induced Thrombocytopenia - GL-2045 - GSK-2285921 - Hetrombopag Olamine - HL-161 - LUNAR-TPO - lusutrombopag - MK-8723 - Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Myelo-001 - NMIL-121 - Oligonucleotides to Activate miRNA-150 for Thrombocytopenia - OMS-721 - PEG-VM501 - PHN-013 - plasma (human) - PRT-060318 - PRTX-100 - rivaroxaban For more information visit http://www.researchandmarkets.com/research/jq...ocytopenia
IMMU: 2.98 (+0.09), PTLA: 19.22 (-0.37), PFE: 34.84 (-0.14), BMY: 59.26 (-0.03), GSK: 44.12 (-0.04), RIGL: 2.81 (-0.09), MNTA: 12.33 (+0.39), OMER: 11.22 (-0.12), ANTH: 3.19 (+0.06), MRK: 63.55 (+0.19), NVS: 81.32 (-0.02)

This is Why the Orphan Drug Space is Easing Worries About Broader Biotech Bubble
ACCESSWIRE - Thu Jul 23, 7:00AM CDT
CORAL GABLES, FL / ACCESSWIRE / July 23, 2015 / Since July 2010, the iShares Nasdaq Biotechnology ETF (IBB) has gained more than 370%, rising from $77 on July 12, 2010 to June 2015 highs of $377 a share. A number of leading news media outlets are starting to report that we are in the midst of a biotech bubble, and that this bubble looks set to burst before the end of the year. This is not to say, however, that there are not opportunities in the space going forward.
RTRX: 17.08 (+0.29), LPCN: 3.77 (+0.10), LBIO: 9.15 (-0.05)

Protalex Announces Listing on OTCQB Exchange
BusinessWire - Mon Jul 20, 12:12PM CDT
Protalex, Inc. (OTCQB: PRTX), a clinical-stage biopharmaceutical company, announces that it has been listed for trading on the OTCQB(R) Market exchange in the United States under the symbol "PRTX."

Protalex wins US FDA's orphan drug designation for PRTX-100 to treat immune thrombocytopenia
M2 - Wed Jun 17, 4:25AM CDT
Biopharmaceutical company Protalex (OtherOTC RTX) disclosed on Tuesday the receipt of orphan drug designation from the US Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for PRTX-100 for the treatment of immune thrombocytopenia (ITP).

Protalex Receives Orphan Drug Designation from FDA for PRTX-100 to Treat Immune Thrombocytopenia
BusinessWire - Tue Jun 16, 7:30AM CDT
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to PRTX-100 for the treatment of immune thrombocytopenia (ITP). The OOPD is tasked with evaluating the scientific and clinical data submissions from sponsors to identify and designate products as promising for rare diseases and to further advance scientific development of such promising medical products. PRTX-100, Protalex's lead product, is a highly purified form of Staphylococcal Protein A. The FDA previously accepted the Company's Investigational New Drug (IND) application for a Phase I/II open-label, dose-escalating study of PRTX-100 in adults with persistent/chronic ITP. Protalex expects to enroll its first patient in an ITP study in the third quarter of 2015.

Protalex Announces Findings from Final Cohort of U.S. Phase 1b Trial of PRTX-100 in Active Rheumatoid Arthritis Patients
BusinessWire - Thu Apr 16, 7:30AM CDT
Protalex, Inc. (OTCQB RTX), a clinical-stage biopharmaceutical company, announced that it has completed analysis from the final cohort (Cohort 5) of its U.S.-based multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (RA; the 104 Study). PRTX-100, Protalex's lead drug, is a highly purified form of Staphylococcal Protein A, which is the subject of ongoing clinical development in rheumatoid arthritis RA. Under a separate Investigational New Drug application, the Company will soon commence a clinical trial of PRTX-100 in patients suffering from chronic Immune Thrombocytopenia (ITP), an orphan disease.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 0

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 18

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 210

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 19

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 370

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 358

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 81

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading

Top 5 Most Recently Viewed Articles

BETR Faces Securities Fraud Actions Post-Misleading Statements

Updated Category News Views 123

Unpacking the Legal Drama Around BETR The tale of Better Home & Finance Holding Company (BETR) is like a roadside crash you can't help but stare at. We're talking big, ugly losses and a chance for investors who got roughed up to throw some punches back with a securities fraud class action. The legal honchos at Howard G. Smith's law office are rallying the troops. If...

Continue Reading
Dorian LPG Faces Market Challenges But Holds Strong Financials

Updated Category News Views 133

Dorian LPG Stock Performance Overview In a challenging market environment, Dorian LPG Ltd. (NYSE: LPG) stock has recently touched a 52-week low, with shares falling to $24.86. This significant drop highlights a broader trend in the industry, as the company grapples with headwinds leading to a troubling one-year change of -38.78%. Investors are closely monitoring the stock...

Continue Reading
Copenhagen Airports A/S Annual General Meeting Announcement

Updated Category News Views 115

Upcoming Annual General Meeting of Copenhagen Airports A/S Shareholders are invited to participate in the Annual General Meeting of Copenhagen Airports A/S. This important event will take place on the scheduled date and time, providing an opportunity for stakeholders to engage with the management and stay informed about the company's direction. Notice of Meeting Details...

Continue Reading
Important Notice for Shareholders of KinderCare Learning

Updated Category News Views 131

Key Notice for KinderCare Learning Companies, Inc. Shareholders The Gross Law Firm has issued a crucial notice directed at shareholders of KinderCare Learning Companies, Inc. (NYSE: KLC) regarding a class action lawsuit. This communication is particularly relevant to those who acquired shares during the designated class period. Shareholders are strongly encouraged to make...

Continue Reading
Discover the New Romantic Getaway at Cicada Resort Bali Ubud

Updated Category News Views 350

Welcome to Cicada Resort Bali Ubud Cicada Resort Bali Ubud, Autograph Collection, located in Sebatu's tranquil environment, extends a warm invitation to travelers seeking a romantic retreat. The resort has recently become part of the prestigious Autograph Collection, contributing to its expanding presence in the hospitality space. Embrace Nature and Culture Just a short...

Continue Reading